ORKA Oruka Therapeutics, Inc.
USHealthcareAs of 2026-08-25 11:41
Why ORKA matters now
Oruka Therapeutics, Inc. (ORKA) is a US stock in Healthcare. The latest InvestLog snapshot shows $103.67 with +1.22% on the session and $6.25B in market capitalization; recent performance reads 1-month +25.81% and YTD +138.67%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-31.8M, and EPS of $-0.58. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.4%.
The latest indexable market news headline is "BlackRock Inc. Purchases Shares of 4,990,181 Oruka Therapeutics, Inc. ORKA" from Defense World.
Additional event context on this page matters because analyst consensus is Buy with a median target of $155.50; recent insider activity includes Quinlan Paul T filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
8.20
P/S
0.00
EV/EBITDA
-22.92
DCF Value
$0.90
FCF Yield
-3.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-26.0%
ROA
-23.0%
ROIC
-27.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-31.8M | $-0.58 |
| Q4 2025 | $0.00 | $-29.6M | $-0.54 |
| FY 2025 | $0.00 | $-105.4M | $-2.31 |
| Q3 2025 | $0.00 | $-30.3M | $-0.69 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$149.50
Target (Median)
$155.50
Target Range
$100.00 - $200.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.30
Oruka Therapeutics, Inc. functions as a biotechnology firm primarily dedicated to creating groundbreaking monoclonal antibody therapies. These treatments are designed to address Psoriasis (PsO) along with various other inflammatory and immunological (I&I) conditions. Its current development portfolio includes ORKA-001 and ORKA-002. The company's main operations are based in Menlo Park, CA.